has a Call To Action calling on J&J not to enforce their secondary patents on BDQ.
MSF has been using the tuberculosis (TB) drug bedaquiline for over a decade to treat people in our projects with drug resistant TB. Bedaquiline is much more effective at beating TB than older drugs. It is also an oral drug, replacing earlier medications that had to be administered through painful daily injections. Additionally, bedaquiline does not have the terrible side effects of older TB drugs. There are, today, newer treatments for TB that include bedaquiline and that have the potential to save many more lives of people living with drug resistant TB. But the price of bedaquiline, made by pharma company, Jonhson & Johnson, is too high to allow these new treatments to be rolled out widely. MSF is working to try to ensure more affordable access to bedaquiline for all in need.